Mesoblast Limited
MESO
Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines in the United States, Australia, Singapore, the United Kingdom, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platformā¦ read more
Healthcare
Biotechnology
14 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$17.79
Price-1.93%
-$0.35
1Y
Price
Market Cap
$2.185b
Mid
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-754.5%
EBITDA Margin-960.4%
Net Profit Margin-5.1%
Free Cash Flow MarginRevenue
$5.670m
-0.5%
1y CAGR+3.3%
3y CAGR-16.7%
5y CAGREarnings
-$103.351m
+10.8%
1y CAGR+9.6%
3y CAGR+0.5%
5y CAGREPS
-$0.92
+46.7%
1y CAGR+4.1%
3y CAGR-1.6%
5y CAGRBook Value
$597.442m
$784.683m
Assets$187.241m
Liabilities$128.157m
DebtDebt to Assets
16.3%
-2.1x
Debt to EBITDAFree Cash Flow
-$50.869m
+56.2%
1y CAGR+33.0%
3y CAGR+3.5%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company